Truist Financial Begins Coverage on Viking Therapeutics (NASDAQ:VKTX)
Truist Financial began coverage of Viking Therapeutics (VKTX) with a “buy” rating and an $83.00 price target, implying 159.5% upside from the prior close, according to the firm. Other analysts set targets from $95 to $102 and ratings ranging from “buy” to “sell.” VKTX shares traded at $31.99 midweek; it reported Q1 EPS of ($1.37), missing the ($1.01) consensus.
How this was made
The 30-second read
Why it matters
New analyst coverage can attract incremental capital and lift sentiment, but the most recent reported quarter showed a meaningful EPS miss versus consensus, which can temper enthusiasm until clearer clinical or commercial progress emerges.
Market read
The tradable catalyst is sell-side initiation/targets for VKTX, occurring alongside a recent earnings miss and ongoing institutional accumulation signals.
What to watch
The article lacks specific trial/data catalysts; price action may therefore hinge on analyst revisions and positioning rather than new clinical milestones.
Background
Viking Therapeutics is a clinical-stage biopharma focused on metabolic/endocrine disorders, with lead programs VK2809 (NASH/dyslipidemia) and VK5211 (muscle wasting).
Ticker impact
Truist Financial initiated coverage on Viking Therapeutics with a Buy rating and an $83 price target, implying large upside from the prior close.
Bias toward upside/volatility in the next sessions as traders price in new research coverage; follow-through depends on how the market reconciles the earnings miss versus bullish targets.
The article provides explicit Buy/target from Truist and other bullish targets, but also notes the company missed EPS on April 30, which can cap rallies and increase sensitivity to further catalysts.
Market effects
Biopharma small/mid-cap sentiment may improve modestly as additional sell-side coverage highlights perceived pipeline optionality.
Limited; impact is primarily on US-listed VKTX research/positioning rather than broad regional flows.
Low; the news is analyst-coverage driven with no stated global regulatory or trial outcome.
Counterpoint
Large upside targets may be more optimistic than near-term fundamentals, especially after the company’s EPS miss and ongoing negative P/E profile.
Key entities
- companyViking Therapeutics
Initiated coverage by Truist with Buy rating and $83 target; also recently reported an EPS miss.
- analyst_firmTruist Financial
Started coverage with a Buy rating and $83 price target for VKTX.
- regulatory_sourceSEC EDGAR (insider filing)
Disclosed an insider purchase by Neil William Aubuchon (Form 4 context).
